$CLBT

Cellebrite DI (CLBT) Names Shiven Ramji CEO As Revenue Guidance Is Cut

Cellebrite DI (NasdaqGS: CLBT) announced CEO succession, naming Shiven Ramji, President, Products and Technology, to become CEO. The company also revised its full-year revenue guidance downward versus its prior outlook and reshaped board responsibilities for the transition. The changes affect investors focused on its recurring subscription revenue model.

Original reporting
Published Aug 14, 2026, 12:50 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cellebrite DI (CLBT) Names Shiven Ramji CEO As Revenue Guidance Is Cut — source image
Decision brief

The 30-second read

$CLBTBearishMed
01

Why it matters

The combination of leadership transition and lowered full-year revenue guidance can shift investor expectations for ARR growth trajectory and the cadence of government-related contract timing.

02

Market read

Traders may reprice CLBT on guidance risk and transition execution, especially given the company’s stated dependence on recurring subscription growth.

03

What to watch

The article does not quantify the magnitude of the guidance reduction or specify which revenue components (subscriptions vs services) drove the reset, which could materially change how traders interpret the risk.

Relevance 7/10Novelty 6/10Timing: immediately after the CEO succession and full-year guidance cut announcement

Background

Cellebrite DI provides software and services for legally sanctioned digital investigations and is positioning around recurring, subscription-based revenue.

Company-level read

Ticker impact

$CLBTBearishMedium confidence
Context

Cellebrite DI announced Shiven Ramji as incoming CEO and revised full-year revenue guidance to a lower outlook than previously provided.

Expected impact

Likely negative bias for the stock until investors gain clarity on the guidance drivers and transition execution.

Evidence & confidence

The article’s newest concrete facts are the CEO succession plan and the explicit reduction in full-year revenue guidance, both of which typically pressure valuation multiples and raise execution risk.

Market effects

Highlights execution and guidance risk for subscription-heavy software vendors serving law-enforcement and investigation workflows.

No specific regional demand change is disclosed beyond broad multi-region operations.

Limited, as the article does not cite cross-border contract wins or regulatory actions.

Counterpoint

The CEO change could be a planned succession aligned with the company’s recurring revenue strategy, and the guidance cut may reflect timing rather than structural demand weakness.

Key entities

  • Cellebrite DI

    Nasdaq-listed digital investigation software and services provider that announced CEO succession and revised full-year revenue guidance downward.

  • Shiven Ramji

    President, Products and Technology, set to take over as CEO as part of the planned succession.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.